Lancet (London, England)AdultAgedFemaleHumansMale
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.
Laurie H Sehn, Kai Hübel, Stefano Luminari, Christian W Scholz, Antonio Salar, Shankara Paneesha, Björn Engelbrekt Wahlin, Panayiotis Panayiotidis, Hui-Peng Lee, Ana Jiménez-Ubieto, Juan-Manuel Sancho, Tae Min Kim, Eva Domingo Domenech, Takahiro Kumode, Christina Poh
Published: 202610.1016/S0140-6736(25)01778-7
Abstract
BACKGROUND: Follicular lymphoma is characterised by episodes of remission and relapse, with patients requiring multiple lines of therapy. Lenalidomide plus rituximab is a commonly used immunotherapy combination in patients with relapsed or refractory…
Preview only. Read the full abstract at the source